| Autor: |
Melissa Jones, Stephanie Denieffe, Ciara Griffin, Willard Tinago, Maria C. Fitzgibbon |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Practical Laboratory Medicine, Vol 8, Iss , Pp 95-104 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
2352-5517 |
| DOI: |
10.1016/j.plabm.2017.05.005 |
| Popis: |
Objectives: Creatinine is the biomarker of choice for use in estimates of kidney function in oncology patients. However as non-renal factors such as muscle mass can influence creatinine concentrations, we evaluated cystatin C as an alternative biomarker and its incorporation in GFR estimating formulae in an oncology setting. Measured GFR is infrequently undertaken in adult clinical practice with the consequent reliance on calculated GFR for patient assessment. Design and methods: Cystatin C and creatinine concentrations were evaluated from 134 oncology patients prior to commencing chemotherapeutic cycles. Estimates of creatinine clearance (Cockroft-Gault) and GFR (using Hoek, Jonsson, MDRD and CKD-EPI) were evaluated. Cystatin C-based GFR estimates (using CKD-EPI CysC and CKD-EPI SCr/CysC) were compared with the creatinine-based GFR estimates (CG, MDRD and CKD-EPI SCr) within the GFR ranges of 60–89, 45–59 and ≤44 mL/min/1.73 m2. Results: Cystatin C concentrations were significantly higher in oncology patients both prior to commencing chemotherapy (F: P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
